论文部分内容阅读
由阿斯利康公司和Nektar生物医药公司联合开发的药物naloxegol于2014年9月16日获FDA批准上市[1],商品名为Movantik。该药为口服药物,属于外周μ-阿片受体拮抗剂,为纳洛酮的聚乙二醇化衍生物,临床上用于治疗慢性非癌性疼痛的成人患者因使用阿片类药物而引起的便秘。Naloxegol的中文化学名称:17-烯丙基-4,5α-环氧-3,14-二羟基-6α-(3,6,9,12,15,18,21-七氧代二十一烷-1-基)吗啡喃;英文化学名称:17-allyl-4,5alpha-epoxy-3,14-dihydroxy-6 alpha-(3,6,9,12,15,18,21-heptaoxadocos-1-
Naloxegol, a drug jointly developed by AstraZeneca and Nektar Biopharmaceutical, was approved by the FDA on September 16, 2014 [1] and is marketed as Movantik. The drug is an oral drug and belongs to the peripheral μ-opioid receptor antagonist, which is a pegylated derivative of naloxone, which is clinically used to treat constipation caused by the use of opioids in adults with chronic non-cancerous pain . Chinese chemical name of Naloxegol: 17-allyl-4,5α-epoxy-3,14-dihydroxy-6α- (3,6,9,12,15,18,21-heptaoxuryicosane 1-yl) morphinan; English name: 17-allyl-4,5alpha-epoxy-3,14- dihydroxy-6 alpha- (3,6,9,12,15,18,21-heptaoxadocos-1-